# A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

> **NCT00724048** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 227 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** ACR16
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00724048
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-24
- **Primary completion:** 2010-07-26
- **Final completion:** 2010-07-26
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724048, "A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00724048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*